Age at diagnosed (years) |
|
|
|
|
|
≤49 years |
17 (63.0%) |
4 (30.8%) |
0.056 |
5 (62.5%) |
0.981 |
>49 years |
10 (37.0%) |
9 (69.2%) |
|
3 (37.5%) |
|
BRCA-germline-mutation status |
|
|
|
|
|
BRCA1 mutation |
18 (66.7%) |
10 (76.9%) |
0.687 |
6 (75.0%) |
0.817 |
BRCA2 mutation |
8 (29.6%) |
3 (23.1%) |
|
2 (25.0%) |
|
BRCA1 and 2 mutations |
1 (3.7%) |
0 (0.0%) |
|
0 (0.0%) |
|
NAC-IDS |
|
|
|
|
|
Yes |
5 (18.5%) |
5 (38.5%) |
0.173 |
0 (0.0%) |
0.189 |
No |
22 (81.5%) |
8 (61.5%) |
|
8 (100.0%) |
|
FIGO stage at diagnosed |
|
|
|
|
|
I/II |
4 (14.8%) |
2 (15.4%) |
0.962 |
2 (25.0%) |
0.502 |
III/IV |
23 (85.2%) |
11 (84.6%) |
|
6 (75.0%) |
|
Primary tumor location |
|
|
|
|
|
Ovary |
26 (96.3%) |
13 (100.0%) |
0.482 |
7 (87.5%) |
0.347 |
Fallopian tube |
1 (3.7%) |
0 (0.0%) |
|
1 (12.5%) |
|
Histologic type |
|
|
|
|
|
High-grade serous |
26 (96.3%) |
12 (92.3%) |
– |
6 (75.0%) |
– |
Serous not specified |
0 (0.0%) |
0 (0.0%) |
|
2 (25.0%) |
|
Endometrioid |
1 (3.7%) |
0 (0.0%) |
|
0 (0.0%) |
|
Clear-cell |
0 (0.0%) |
1 (7.7%) |
|
0 (0.0%) |
|
Residual lesions |
|
|
|
|
|
No |
15 (55.6%) |
8 (61.5%) |
0.932 |
5 (62.5%) |
0.890 |
Yes |
8 (29.6%) |
4 (30.8%) |
|
3 (37.5%) |
|
Unknown a
|
4 (14.8%) |
1 (7.7%) |
|
0 (0.0%) |
|
PFI after 1st line of platinum-containing chemotherapy |
|
|
|
|
|
5-6months |
2 (7.4%) |
0 (0.0%) |
0.222 |
0 (0.0%) |
0.547 |
≥6, <12 months |
6 (22.2%) |
6 (46.2%) |
|
3 (37.5%) |
|
≥12 months |
19 (70.4%) |
7 (53.8%) |
|
5 (62.5%) |
|
PFI after 2nd line of platinum-containing chemotherapy |
|
|
|
|
|
≥6, <12 months |
20 (74.1%) |
8 (61.5%) |
0.418 |
5 (62.5%) |
0.525 |
≥12 months |
7 (25.9%) |
5 (38.5%) |
|
3 (37.5%) |
|
PFI before fourth-line chemotherapy |
|
|
|
|
|
<6 months |
0(0.0%) |
0(0.0%) |
– |
8(100.0%) |
0.000**
|
≥6, <12 months |
1(3.7%) |
11(84.6%) |
|
0(0.0%) |
|
≥12 months |
26 (96.3%) |
2(15.4%) |
|
0(0.0%) |
|